Key result
Tegoprazan shows similar platelet reactivity to PPIs in patients on clopidogrel post-PCI.
Why the study?
Data on the interactions between clopidogrel and tegoprazan are limited.
Does tegoprazan compared to PPIs affect platelet reactivity in patients treated with clopidogrel after coronary stenting?
Cohort (n=262)
No
Does tegoprazan compared to PPIs affect platelet reactivity in patients treated with clopidogrel after coronary stenting?
Tegoprazan does not significantly affect clopidogrel-induced platelet reactivity compared to traditional PPIs, suggesting it is a safe gastroprotective alternative for patients on DAPT after PCI.
May support tegoprazan as PPI alternative post-PCI; hypothesis-generating and should not yet change practice.
BACKGROUND/AIMS: Data on the interactions between clopidogrel and tegoprazan are limited. We compared the effects of tegoprazan and proton-pump inhibitors (PPIs) on platelet reactivity. METHODS: Using database data from March 2020 to January 2023, we retrospectively evaluated 262 patients who were taking either tegoprazan (n = 107) or PPIs (n = 155) combined with dual antiplatelet therapy, including aspirin and clopidogrel, after percutaneous coronary intervention. Platelet reactivity was assessed using VerifyNow P2Y12 assays. RESULTS: Platelet reaction unit (PRU) values at 3 (157 ± 8 vs. 162 ± 6, p = 0.659), 6 (167 ± 9 vs. 158 ± 7, p = 0.370), and 12 months (155 ± 10 vs. 164 ± 7, p = 0.448) were similar between groups. The prevalence of high on-treatment platelet reactivity, defined as ≥ 253 PRU, was also similar between the groups at 3 (10.3% vs. 10.2%, p = 0.976), 6 (7.0% vs. 8.2%, p = 1.000), and 12 months (4.3% vs. 9.0%, p = 0.503). CONCLUSION: There was no significant difference in platelet reactivity between the tegoprazan and PPI groups in patients undergoing PCI and receiving dual antiplatelet therapy with clopidogrel.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) conducted a cohort in Coronary artery disease requiring percutaneous coronary intervention and dual antiplatelet therapy (n=262). Tegoprazan vs. Proton-pump inhibitors (PPIs) was evaluated on Platelet reaction unit (PRU) value at 3 months (Mean difference -4, 95% CI -23 to 15, p=0.659). Tegoprazan resulted in similar platelet reactivity compared to proton-pump inhibitors at 3, 6, and 12 months in patients receiving clopidogrel after percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: